1 active not recruiting, 1 withdrawn. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Active not recruiting 1, Withdrawn 1 |
Follow BNT162b5: new trials by email Literature Review of BNT162b5 trials Research Report on BNT162b5
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial Pfizer Bivalent COVID-19 Vaccine, Moderna Bivalent mRNA vaccine - HIV, Organ Transplantation | Phase 3 | Active not recruiting | Monash University | 960 | 2022-12-01 | 2025-10-03 |
| COVID-19 Fourth Dose Study in Australia Tozinameran, Elasomeran, Bivalent Pfizer-BioNTech - COVID-19 | Phase 3 | Withdrawn | Murdoch Childrens Research Institute | 2022-05-02 | 2024-03-15 |
COVID-19 (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, Non-Hodgkin (1) · Multiple Myeloma (1)
Monash University (1) · Murdoch Childrens Research Institute (1)
Australia (2)
James H McMahon, MBBS PhD (1) · Kim Mulholland, MD/Prof (1)